Search Menu

Conference reports

8th Conference on Retroviruses and Opportunistic Infections, February 4-8 2001, Chicago, USA

From talk to action in fighting AIDS in the developing countries: 8th Retrovirus Conference opening session

Differentiating within and between drug classes: sometimes it’s toxicity, sometimes its efficacy

Intermittent versus continuous HAART

Viral load “blips” and eventual rebound

Interaction between garlic and saquinavir and underreporting of alternative treatment use

Solid organ transplant in HIV/hepatitis co-infected patients

HIV and women – overview

Update on HIV drug resistance

Update and review of bone studies

Treatment interruptions, structured and unplanned, immunotherapy and what’s in store

Primary infection and treatment issues

Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK

Treatment strategies in 2000: planning first-line (and therefore, second-line) therapy

When should HAART be started?

MDR resistance transmission increases in the UK

Interferon-gamma treatment in azole-resistant oropharyngeal candidiasis

Further reports of avascular necrosis (AVN) and changes in bone mineral density (BMD)

Clinical issues arising from a single treatment interruption

A review of new anti-HIV drugs in development

Antiretroviral therapy in children, women and intravenous drug users

Treatment of HIV+ subjects co-infected with hepatitis B or C: safety and efficacy comparison of ABT 378/r versus nelfinavir from a phase III blinded randomised clinical trial

Interferon-alpha and ribavarin therapy for hepatitis C in HIV coinfected patients

Lack of significant viral load alterations of hepatitis B virus (HBV) and hepatitis C virus (HCV) during treatment with interleukin-2 and HAART

Child protection issues around starting efavirenz in a mother on maintenance methadone

Structured treatment interruptions

Adherence and HAART: unique approaches to evaluating and improving adherence discussed

Reports on lipodystrophy and metabolic complications

Opportunistic infections in the HAART era

2nd International Workshop on Adverse Drug Reactions and Lipodystrophy, Toronto, Canada, 13-15 September 2000

Lipodystrophy: the current state of play

Metabolic effects – bone density and avascular necrosis

Lipoatrophy and facial wasting

Lactic acidosis

Lipodystrophy and metabolic changes in children

40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 September 2000

Mitochondrial toxicity reports

Treatment interruption and salvage therapy

Are gender-related differences in viral load present in infants and children?

Immune reconstitution in children treated with HAART is independent of age

Pharmacokinetics in children and infants

Opportunistic illness and viral hepatitis co-infection

XIII International AIDS Conference, Durban, South Africa, 9-14th July 2000

Mother-to-child transmission, maternal health and women’s access to care

The M in MTCT: questions about HIV-positive mothers

First report of ABT-378/r use in children

Nelfinavir doses should be increased in infants less than 3 months

Metabolic and lipodystropy issues: confusion continues to reign

Switching studies: Can viral load be maintained and metabolic or fat redistribution significantly improved?

Commentary on STI talk, early entry inhibitor research, increase in viral replication seen in isolates in presence of NNRTIs

New developments in affordable antiretroviral therapy: intermittent treatment

Cannabinoids effect on HIV-1 viral load and appetite

IL-2 without HAART may delay need for antiretroviral treatment

New potential dual NNRTI-based combinations

Once-daily protease-based regimens

Mitochondrial DNA (mtDNA) damage in semen as surrogate marker for nucleoside analogue toxicity

Antiretrovirals and fertility – implications for couples looking to conceive

Incidence of adverse events at 4 weeks correlates with adherence and virologic failure at 4 months

Prednisone and nevirapine rash

The prevalence of hypogonadism in HIV positive patients receiving HAART

Human papilloma virus and HIV

4th International Workshop on HIV Drug Resistance and Treatment Strategies, 12-16 June 2000, Sitges, Spain

Tenofovir (PMPA), defining cross-resistance profiles

DAPD shows activity in vitro against multidrug-resistant HIV but initial results from monotherapy in treatment experienced subjects are disappointing

Mycophenalate mofetil in patients with advanced disease and multidrug resistant HIV

Post navigation